Humana Inc (HUM) Stock AnalysisHUMStock AnalysisHumana Inc

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Humana Inc is currently trading at $385.54, with a forward P/E ratio of 42.92, indicating high valuation. The RSI is at 49.63, suggesting the stock is neither overbought nor oversold. While the stock has shown a year-to-date change of +45.77%, the recent earnings report showed a surprise of +22.35% but a price drop of -5.99% post-earnings. The main risk is the high forward P/E ratio, which indicates that the stock may be overvalued relative to its earnings growth potential.

19 analysts cover HUM: 12 rate it Buy, 7 Hold and 0 Sell. The average price target is 290.39.